Ironwood Pharmaceuticals market cap is $1.4 b, and annual revenue was $346.64 m in FY 2018

Ironwood Pharmaceuticals Net income (Q2, 2019)12.3 M

Ironwood Pharmaceuticals EBIT (Q2, 2019)21.6 M

Ironwood Pharmaceuticals Cash, 30-Jun-201998.9 M

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Revenue | 22.9m | 76.4m | 149.6m | 274.0m | 298.3m | 346.6m |

| 234% | 96% | 83% | |||

## Cost of goods sold | 12.0k | |||||

## Gross profit | 149.5m | |||||

| 100% | |||||

## R&D expense | 102.4m | 108.7m | 139.5m | 148.2m | 166.5m | |

## General and administrative expense | 123.2m | 125.2m | 173.3m | 233.1m | 241.3m | |

## Operating expense total | 225.6m | 234.0m | 312.8m | 381.4m | 407.8m | |

## EBIT | (252.0m) | (169.4m) | (102.1m) | (51.9m) | (77.4m) | (238.9m) |

| (1101%) | (222%) | (68%) | (19%) | (26%) | (69%) |

## Interest expense | 21.0m | 31.1m | 39.2m | 36.4m | 37.7m | |

## Net Income | (272.8m) | (189.6m) | (142.7m) | (81.7m) | (116.9m) | (282.4m) |

USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 52.2m | 65.1m | 86.8m | 69.2m | 81.1m | 65.7m | 68.7m | 102.2m | ||||||||||

## Cost of goods sold | 2.0m | 1.9m | 10.5m | 12.0k | 8.2m | |||||||||||||

## R&D expense | 23.0m | 27.1m | 22.1m | 25.1m | 26.6m | 28.6m | 25.8m | 31.8m | 31.7m | 37.5m | 33.7m | 37.3m | 37.1m | 36.5m | 38.9m | 46.8m | 54.0m | 28.8m |

## General and administrative expense | 30.3m | 29.9m | 29.3m | 28.5m | 30.3m | 33.0m | 30.4m | 36.2m | 36.9m | 45.0m | 55.6m | 57.8m | 61.8m | 61.9m | 68.4m | 55.2m | 64.7m | 43.2m |

## Operating expense total | 53.3m | 57.1m | 51.4m | 53.7m | 57.0m | 61.6m | 56.3m | 68.0m | 68.6m | 82.5m | 89.3m | 95.1m | 98.8m | 98.4m | 203.3m | 102.0m | 118.7m | 72.0m |

## EBIT | (56.6m) | (44.4m) | (55.1m) | (36.7m) | (28.1m) | (42.0m) | (26.2m) | (2.0m) | (15.3m) | (28.3m) | (39.7m) | (41.0m) | (19.4m) | (35.9m) | (39.9m) | (169.1m) | (54.4m) | 21.6m |

| (76%) | (63%) | (22%) | (52%) | (49%) | (257%) | (79%) | 21% | ||||||||||

## Interest expense | 5.3m | 5.3m | 5.3m | 5.3m | 5.2m | 5.9m | 10.0m | 9.9m | 9.8m | 9.8m | 9.0m | 9.0m | 9.1m | 9.3m | 9.4m | 9.5m | 9.6m | 9.4m |

## Net Income | (61.8m) | (49.6m) | (60.4m) | (42.0m) | (33.2m) | (48.0m) | (47.4m) | (13.3m) | (21.7m) | (33.2m) | (52.5m) | (44.2m) | (32.3m) | (43.1m) | (49.4m) | (174.4m) | (59.3m) | 12.3m |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Cash | 75.5m | 74.3m | 261.3m | 54.0m | 125.7m | 173.2m |

## Accounts Receivable | 513.0k | 10.0k | 2.9m | 933.0k | 3.2m | 21.0m |

## Inventories | 22.1m | 10.6m | 6.3m | 1.1m | 735.0k | |

## Current Assets | 229.1m | 289.7m | 500.2m | 380.2m | 311.6m | 266.4m |

## PP&E | 37.4m | 29.8m | 21.1m | 20.5m | 17.3m | 17.3m |

## Goodwill | 785.0k | 785.0k | 785.0k | |||

## Total Assets | 279.0m | 333.5m | 619.1m | 709.8m | 605.7m | 332.1m |

## Accounts Payable | 10.1m | 9.8m | 8.6m | 17.7m | 16.0m | 18.1m |

## Short-term debt | 1.1m | 1.2m | 2.6m | 6.2m | 4.1m | |

## Current Liabilities | 41.0m | 60.5m | 76.5m | 91.1m | 66.0m | 119.5m |

## Long-term debt | 174.7m | 249.2m | ||||

## Total Debt | 175.8m | 2.6m | 6.2m | 253.3m | ||

## Common Stock | 103.0k | 125.0k | 127.0k | 133.0k | 137.0k | 154.0k |

## Additional Paid-in Capital | 815.9m | 1.1b | 1.2b | 1.3b | 1.3b | 1.4b |

## Retained Earnings | (777.8m) | (967.4m) | (1.1b) | (1.2b) | (1.3b) | (1.6b) |

## Total Equity | 38.2m | 88.6m | 95.1m | 66.7m | 9.8m | |

## Debt to Equity Ratio | 4.6 x | 0.1 x | ||||

## Debt to Assets Ratio | 0.6 x | 0 x | ||||

## Financial Leverage | 7.3 x | 3.8 x | 6.5 x | 10.6 x | 61.5 x |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Net Income | (272.8m) | (189.6m) | (142.7m) | (81.7m) | (116.9m) | (282.4m) |

## Depreciation and Amortization | 11.7m | 12.3m | 11.6m | 10.3m | 8.4m | 6.1m |

## Accounts Receivable | (1.7m) | (24.0m) | (28.7m) | (10.3m) | (17.3m) | |

## Inventories | (11.9m) | (3.9m) | 2.6m | (3.1m) | 346.0k | |

## Accounts Payable | (11.7m) | 1.4m | ||||

## Cash From Operating Activities | (273.4m) | (155.6m) | (106.9m) | (25.4m) | (99.6m) | (70.9m) |

## Purchases of PP&E | (9.6m) | (3.5m) | (4.0m) | (4.2m) | (4.2m) | (8.6m) |

## Cash From Investing Activities | (101.4m) | (56.6m) | 151.5m | 88.9m | ||

## Cash From Financing Activities | 313.6m | 210.9m | 303.1m | (4.2m) | 19.8m | 30.1m |

## Interest Paid | 18.4m | 19.6m | 22.7m | 24.5m | 20.4m | 18.2m |

USD | Y, 2019 |
---|---|

## Financial Leverage | -1.4 x |